RH 1

Drug Profile

RH 1

Alternative Names: RH-1

Latest Information Update: 10 Sep 2012

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cancer Research Technology; University of Colorado at Denver; University of Salford
  • Developer Allos Therapeutics
  • Class Antineoplastics; Aziridines; Benzoquinones; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA cross linking agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Non-Hodgkin's lymphoma; Solid tumours

Most Recent Events

  • 06 Sep 2012 Allos Therapeutics has been acquired by Spectrum Pharmaceuticals
  • 09 Mar 2009 Rh 1 is available for licensing outside the US (http://www.allos.com)
  • 14 Nov 2007 Phase-I clinical trials in Non-Hodgkin's lymphoma in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top